NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced results from an independent proteomic analysis conducted at the Technion - Israel Institute of Technology. which evaluated multiple production batches of NurExone's exosomes. The results
Biotechnology, Pharmaceuticals, Health
2026-02-10 4:03 PM EST | NurExone Biologic Inc.
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2025 Results with 58% Revenue Growth and Positive Normalized Operating Income
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to report preliminary unaudited financ
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-10 7:30 AM EST | Neural Therapeutics Inc.
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology. The peer-reviewed article reports resu
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-02-10 7:27 AM EST | Cardiol Therapeutics Inc.
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the American Urological Asso
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-10 7:00 AM EST | Theralase Technologies Inc.
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary IN
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-10 7:00 AM EST | Phio Pharmaceuticals Corp.
Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a major clinical milestone for its portfolio company, Inretio. The medical device innovator has successfully completed the first cohort of the First-in-Human (FIH) study for the PREVA™ Neuro-Thrombectomy System, moving
Technology, Biotechnology, Health
2026-02-10 7:00 AM EST | Therma Bright Inc.
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® for antibody-drug conjugate ("ADC") applications. The discussion brought together complementary
Biotechnology, Pharmaceuticals, Health
2026-02-10 3:15 AM EST | Defence Therapeutics Inc.
TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super-Pharm, Israel's largest and most prominent pharmacy and health-retail chain, operating nationwide and serving millions of consumers annually.
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-10 3:00 AM EST | TempraMed Technologies Ltd.
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme. The export included 1,000 of Optimi's MDMA capsules in a standardised 60 mg dosage form, supplied for use in authorised cl
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-09 7:00 AM EST | Optimi Health Corp.
PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents". The international patent application covers innovative methods and formulations aimed at ad
Biotechnology, Pharmaceuticals, Health
2026-02-09 3:00 AM EST | PreveCeutical Medical Inc.
iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete
Woburn, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone delivers a fully integrated, live marketplace that connects customer requests with supplier inventories, enabling streamlined operations, reduced costs, and a foundation for future growth. Chief Executive Off
2026-02-06 9:30 AM EST | iSpecimen Inc.
iSpecimen Achieves Rapid Procurement Milestone for Influenza Research
Lexington, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the strength, responsiveness, and reliability of its site network. Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected
2026-02-06 8:20 AM EST | iSpecimen Inc.
TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed initial sales of VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med to pharmacies operated by Maccabi Healthcare Services ("Maccabi") and has launched a national i
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-06 3:00 AM EST | TempraMed Technologies Ltd.
OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is honored to celebrate the passage of the Mikaela Naylon Give Kids A Chance Act. Mikaela, like so many other children, courageously battled pediatric cancer - specifically Osteosarcoma. Her legacy through this legislation will accelerate critical opportunities for research and therapeutic
2026-02-04 12:45 PM EST | OS Therapies
Bloom Burton & Co. Announces the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce the launch of the 2026 Bloom Burton Award and to open nomination submissions from the public at large on or before March 27, 2026. The finalists for the 2026 Bloom Burton Award will be announced at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place at the Metro Toronto Convention Centre from April 21-22, 2026.
Technology, Biotechnology, Investment Banking, Health
2026-02-04 8:25 AM EST | Bloom Burton & Co. Inc.
Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement
British Columbia and Sacramento, California--(Newsfile Corp. - February 4, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its January 28, 2026 annou
2026-02-04 8:00 AM EST | Izotropic Corporation
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to provide an update on the Phase II clinical study for bladder cancer. To date, 90 patients have been enrol
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-04 7:00 AM EST | Theralase Technologies Inc.
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at World ADC Europe 2026, taking place February 23–26, 2026, in London, UK. Defence will showcase its proprietary Accum® platform, a breakthrough intracellular delivery technology d
Biotechnology, Pharmaceuticals, Health
2026-02-04 3:15 AM EST | Defence Therapeutics Inc.
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 12, 2026 to discuss Medexus's results for its third fiscal quarter ended December 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on February 11, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-03 5:30 PM EST | Medexus Pharmaceuticals Inc.
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurological conditions, is pleased to announce that the Japan Patent Office has granted Japanese Patent No. 2022-554855, titled "Purine Compounds for Treating Disorders
2026-02-03 4:30 PM EST | Marvel Biosciences Corp.